Early experiences with usage of injectable cabotegravir (CAB-LA) among Kenyan and Ugandan adults participating in the SEARCH Dynamic Choice HIV Prevention trial: a qualitative study

AUTHORS

C.S. Camlin¹, C. Akatukwasa², J. Johnson-Peretz¹, T. Arunga³, F. Atwine², A. Onyango³, L. Owino³, G. Chamie⁴, L.B. Balzer⁵, M. Czarzowski⁶, E. Kakande², H. Sunday², N. Sutter⁴, M.R. Kamya^2,7, J. Ayieko³, M.L. Petersen⁵, D.V. Havlir⁴, J. Kabami²


INSTITUTIONS

¹University of California, San Francisco, Obstetrics, Gynecology & Reproductive Sciences, San Francisco, United States, ²Infectious Diseases Research Collaboration, Kampala, Uganda, ³Kenya Medical Research Institute, Kisumu, Kenya, ⁴University of California, San Francisco, Medicine, San Francisco, United States, ⁵University of California, Berkeley, Biostatistics, Epidemiology, and Computational Precision Health, Berkeley, United States, ⁶ViiV Healthcare, Durham, United States, ⁷Makerere University College of Health Sciences, Medicine, Kampala, Uganda